Outcome prediction for renal cell carcinoma: evaluation of prognostic factors for tumours divided according to histological subtype

References

• Srigley J. R., Hutter R. V. P., Gelb A. B., et al. Current prognostic factors – renal cell carcinoma. Cancer 1997; 80: 994–6
   PubMed Web of Science ®Google Scholar
• Delahunt B., Eble J. N. History of the development of classification of renal cell neoplasia. Clin Lab Med 2005; 25: 231–46
   PubMed Web of Science ®Google Scholar
• Amin M. B., Amin M. B., Tamboli P., et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms. An experience of 405 cases. Am J Surg Pathol 2002; 26: 281–91
   PubMed Web of Science ®Google Scholar
• Moch H., Grasser T., Amin M. B., et al. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma. A Swiss experience with 588 tumors. Cancer 2000; 89: 604–14
   PubMed Web of Science ®Google Scholar
• Cheville J. C., Lohse C. M., Zincke H., Weaver A. L., Blute M. L. Comparison of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 2003; 27: 612–24
   PubMed Web of Science ®Google Scholar
• Kim H., Cho N. H., Kim D., et al. Renal cell carcinoma in South Korea: A multicenter study. Hum Pathol 2004; 35: 1556–63
   PubMed Web of Science ®Google Scholar
• Patard J., Leray E., Rioux‐Leclercq N., et al. Prognostic value of histologic subtypes in renal cell carcinoma: A multicenter experience. J Clin Oncol 2005; 23: 2763–71
   PubMed Web of Science ®Google Scholar
• Ljungberg B., Alamdri F. I., Stenling R., et al. Prognostic significance of the Heidelberg classification of renal cell carcinoma. Eur Urol 1999; 36: 565–9
   PubMed Web of Science ®Google Scholar
• Gudbjartsson T., Hardarson S., Petursdottir V., et al. Histological subtyping and nuclear grading of renal cell carcinoma and their implications for survival: A retrospective nation‐wide study of 629 patients. Eur Urol 2005; 48: 593–600
   PubMed Web of Science ®Google Scholar
• Delahunt B., Eble J. N. Papillary renal cell carcinoma: A clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 1997; 10: 537–44
   PubMed Web of Science ®Google Scholar
• Leroy X., Zini L., Leteurtre E., et al. Morphologic subtyping of papillary renal cell carcinoma. Correlation with prognosis and differential expression of MUC1 between the two subtypes. Mod Pathol 2002; 15: 1126–30
   PubMed Web of Science ®Google Scholar
• Delahunt B., Eble J. N., McCredie M. R. E., et al. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Hum Pathol 2001; 32: 590–5
   PubMed Web of Science ®Google Scholar
• Pignot G., Elie C Conquy S., et al. Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification. Urology 2007; 69: 230–5
   PubMed Web of Science ®Google Scholar
• Alloy Y., Ouazana D., Boucher E., Thiounn N., Vieillefond A. Papillary renal cell carcinoma. Prognostic value of morphological subtypes in a clinicopathological study of 43 cases. Virchows Arch 2003; 442: 336–42
   PubMed Web of Science ®Google Scholar
• Tickoo S., Reuter V. Subtyping of papillary renal cell carcinoma. A clinicopathologic study of 103. Mod Pathol 2001; 14: 124A (abstr)
   Web of Science ®Google Scholar
• Xang X. J., Tan M. H., Kim H. L., et al. A molecular subclassification of papillary renal cell carcinoma. Cancer Res 2005; 65: 5628–31
   PubMed Web of Science ®Google Scholar
• Sika‐Paotonu D., Bethwaite P. B., McCredie M. R. E., Jordan T. W., Delahunt B. Nucleolar grade but not Fuhrman grade is applicable to papillary renal cell carcinoma. Am J Surg Pathol 2006; 30: 1091–6
   PubMed Web of Science ®Google Scholar
• Delahunt B. Histopathologic prognostic indicators for renal cell carcinoma. Semin Diagn Pathol 1998; 15: 68–76
   PubMed Web of Science ®Google Scholar
• Fuhrman S. A., Lasky L. C., Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6: 655–63
   PubMed Web of Science ®Google Scholar
• Ficarra V., Martignoni G., Maffei N., et al. Original and reviewed nuclear grading according to the Fuhrman system: a multivariate analysis of 388 patients with conventional renal cell carcinoma. Cancer 2005; 103: 68–75
   PubMed Web of Science ®Google Scholar
• Lohse C. M., Blute M. L., Zincke H., Weaver A. L., Cheville J. C. Comparison of standardized and non‐standardized nuclear grade of renal cell carcinoma to predict outcome among 2,042 patients. Am J Clin Pathol 2002; 118: 877–86
   PubMed Web of Science ®Google Scholar
• Cheville J. C., Zincke H., Lohse C. M., et al. pT1 clear cell renal cell carcinoma. A study of the association between MIB‐1 proliferative activity and pathologic features and cancer specific survival. Cancer 2002; 94: 2180–4
   PubMed Web of Science ®Google Scholar
• Lanigan D., Conroy R., Barry‐Walsh C., et al. A comparative analysis of grading systems in renal adenocarcinoma. Histopathology 1994; 24: 473–6
   PubMed Web of Science ®Google Scholar
• Nazeer T., Amin M. B., Delahunt B., et al. Interobserver variability of nuclear grading in renal cell carcinoma. Mod Pathol 1998; 11: 91A
   Web of Science ®Google Scholar
• Murphy W. M., Grignon D. J., Perlman E. Tumors of the Kidney, Bladder and Related Structures. AFIP, Washington 2004, 4th Series, Fascicle 1
   Google Scholar
• Delahunt B., Sika‐Paotonu D., Bethwaite P. B., et al. Fuhrman grading is not appropriate for chromophobe renal cell carcinoma. Am J Surg Pathol 2007; 31: 957–60
   PubMed Web of Science ®Google Scholar
• Delahunt B. Sarcomatoid renal cell carcinoma: The final common dedifferentiation pathway of renal epithelial malignancies. Pathology 1999; 31: 185–90
   PubMed Web of Science ®Google Scholar
• Cheville J. C., Lohse C. M., Zincke H., et al. Sarcomatoid renal cell carcinoma. An examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol 2004; 28: 435–41
   PubMed Web of Science ®Google Scholar
• Kuroima K., Kinoshita Y., Shiratsuchit H., et al. Renal cell carcinoma with rhabdoid features: an aggressive neoplasm. Histopathology 2002; 41: 538–48
   PubMed Web of Science ®Google Scholar
• Tannapfel A., Hahn H. A., Katalinic A., et al. Prognostic nature of ploidy and proliferation markers in renal cell carcinoma. Cancer 1996; 77: 164–71
   PubMed Web of Science ®Google Scholar
• Delahunt B., Ribas J. L., Nacey J. N., Bethwaite P. B. Nucleolar organizer regions and prognosis in renal cell carcinoma. J Pathol 1991; 164: 31–7
   PubMed Web of Science ®Google Scholar
• Delahunt B., Bethwaite P. B., Thornton A., Ribas J. L. Proliferation of renal cell carcinoma assessed by fixation‐resistant polyclonal Ki‐67 antibody labeling. Correlation with clinical outcome. Cancer 1995; 75: 2714–9
   PubMed Web of Science ®Google Scholar
• Delahunt B., Kittelson J. M., McCredie M. R. E., et al. Prognostic importance of tumor size for localized conventional (clear cell) renal cell carcinoma. Cancer 2002; 94: 658–64
   PubMed Web of Science ®Google Scholar
• Gelb A. B., Sudilovsky D., Wu C. D., Weiss L. M., Medeiros L. J. Appraisal of intratumoral microvessel diversity, MIB‐1 score, DNA content and p53 protein expression as prognostic indicators in patients with locally confined renal cell carcinoma. Cancer 1997; 80: 1768–75
   PubMed Web of Science ®Google Scholar
• Moch H., Sauter G., Buchholz N., et al. Epidermal growth factor receptor expression is associated with rapid tumour cell proliferation in renal cell carcinoma. Hum Pathol 1997; 28: 1255–9
   PubMed Web of Science ®Google Scholar
• Kankuri M., Soderstrom K. O., Pelliniemi T. T., et al. The association of immunoreactive p53 and Ki‐67 with T‐stage, grade, occurrence of metastases and survival in renal cell carcinoma. Anticancer Res 2006; 26: 3825–33
   PubMed Web of Science ®Google Scholar
• Yildiz E., Gokce G., Kilicarslan H., et al. Prognostic value of the expression of Ki‐67, CD44 and vascular endothelial growth factor, and microvessel invasion in renal cell carcinoma. BJU Int 2004; 93: 1087–93
   PubMed Web of Science ®Google Scholar
• Delahunt B., Eble J. N., McCredie M. R. E. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Hum Pathol 2001; 32: 590–5
   PubMed Web of Science ®Google Scholar
• Yang R. M., Naitoh J., Hengst L., Reed S. I. Translational control of p27Kip1 accumulation during the cell cycle. Science 1996; 271: 1861–4
   PubMed Web of Science ®Google Scholar
• Migita T., Oda Y., Naito S., Tsuneyoshi M. Low‐expression of p27Kip1 is associated with tumor size and poor prognosis in patients with renal cell carcinoma. Cancer 2002; 94: 973–9
   PubMed Web of Science ®Google Scholar
• Weiss R. H., Borowsky A. D., Seligson D., et al. p21 is a prognostic marker for renal cell carcinoma. Implications for novel therapeutic approaches. J Urol 2007; 177: 63–9
   PubMed Web of Science ®Google Scholar
• Lipponen P., Eskelinen M., Hietala K., et al. Expression of proliferating cell nuclear antigen (PC10), p53 protein and c‐erbB‐2 in renal adenocarcinoma. Int J Cancer 1994; 57: 275–80
   PubMed Web of Science ®Google Scholar
• Oda H., Nakatsuru Y., Ishikawa T. Mutation of the p53 gene and p53 protein over‐expression are associated with sarcomatoid transformation in renal cell carcinoma. Cancer Res 1995; 55: 658–62
   PubMed Web of Science ®Google Scholar
• Imai Y., Strohmeyer T. G., Fleischhacker M., Slamon D. J., Koeffler H. P. p53 mutations and MDM‐2 amplification in renal cell cancers. Mod Pathol 1994; 7: 766–70
   PubMed Web of Science ®Google Scholar
• Phuoc N. B., Ehara H., Gotoh T., et al. Immunohistochemical analysis with multiple antibodies in search of prognostic markers for clear cell renal cell carcinoma. Urology 2007; 69: 843–8
   PubMed Web of Science ®Google Scholar
• Gobe G., Rubin M., Williams G Sawczuk I., Buttyan R. Apoptosis and expression of Bcl‐2, Bcl‐XL and Bax in renal cell carcinomas. Cancer Invest 2002; 20: 324–32
   PubMed Web of Science ®Google Scholar
• Dosquet C., Condert M. C., Lepage E., Cabane J., Richard E. Are angiogenic factors, cytokines and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?. Clin Cancer Res 1997; 3: 2451–8
   PubMed Web of Science ®Google Scholar
• Itoi T., Yamana K., Bilim V., Tokahashi K., Tomita F. Impact of frequent Bcl‐2 expression on better prognosis in renal cell carcinoma?. Br J Cancer 2004; 90: 2000–5
   Web of Science ®Google Scholar
• Joo H. J., Oh D. K., Kim Y. S., Lee K. B., Kim S. J. Increased expression of caveolin‐1 and microvessel density correlates with metastases and poor prognosis in clear cell renal cell carcinoma. BJU Int 2004; 93: 291–6
   PubMed Web of Science ®Google Scholar
• Fukata S., Inone K., Kamada N., et al. Levels of angiogenesis and expression of angiogenesis‐related genes are prognostic for organ‐specific metastases of renal cell carcinoma. Cancer 2005; 103: 931–42
   PubMed Web of Science ®Google Scholar
• MacLennan G. T., Bostwick D. G. Microvessel density in renal cell carcinoma: Lack of prognostic significance. Urology 1995; 46: 27–30
   PubMed Web of Science ®Google Scholar
• Lee J. S., Kim H. S., Jung J. J., Park C. S., Lee M. C. Expression of vascular endothelial growth factor in renal cell carcinoma and the relation to angiogenesis and p53 protein expression. J Surg Oncol 2001; 77: 55–60
   PubMed Web of Science ®Google Scholar
• Delahunt B., Bethwaite P. B., Thornton A. Prognostic significance of microscopic vascularity for clear cell renal cell carcinoma. Br J Urol 1997; 80: 401–4
   PubMedGoogle Scholar
• Yoshimo S., Kato M., Okada K. Evaluation of the prognostic significance of microvessel count and tumor size in renal cell carcinoma. Int J Urol 1998; 5: 119–23
   PubMedGoogle Scholar
• Rioux‐Leclercq N., Epstein J. I., Bansard J. Y., et al. Clinical significance of cell proliferation, microvessel density and CD44 adhesion molecule expression in renal cell carcinoma. Hum Pathol 2001; 32: 1209–15
   PubMed Web of Science ®Google Scholar
• Imao T., Egawa M., Takashima H., Koshida K., Namiki M. Inverse correlation of microvessel density with metastases and prognosis in renal cell carcinoma. Int J Urol 2004; 11: 948–53
   PubMed Web of Science ®Google Scholar
• Sandlund J., Hedberg Y., Bergh A., et al. Endoglin (CD105) expression in human renal cell carcinoma. BJU Int 2006; 97: 706–10
   PubMed Web of Science ®Google Scholar
• Gilcranse M. Z., Guzman‐Paz M., Niehans G., et al. Correlation of CD44S expression in renal clear cell carcinomas with subsequent tumor progression or recurrence. Cancer 1999; 86: 2320–6
   PubMed Web of Science ®Google Scholar
• Jin J. S., Yu C. P., Sun G. H., et al. Increasing expression of fascin in renal cell carcinoma associated with clinicopathological parameters of aggressiveness. Histol Histpathol 2006; 21: 1287–93
   PubMed Web of Science ®Google Scholar
• Petraki C. D., Gregorakis A. K., Vaslamatzis M. M., et al. Prognostic implications of the immunohistochemical expression of human kallikreins 5, 6, 10 and 11 in renal cell carcinoma. Tumour Biol 2006; 27: 1–7
   PubMedGoogle Scholar
• Lidgren A., Hedberg Y., Grankvist K., et al. The expression of hypoxia‐inducible factor 1 alpha is a favorable independent prognostic factor in renal cell carcinoma. Clin Cancer Res 2005; 11: 1129–35
   PubMed Web of Science ®Google Scholar
• Costes V., Liantard J., Picot M‐C., et al. Expression of the Interleukin‐6 receptor in primary renal cell carcinoma. J Clin Pathol 1997; 50: 835–40
   PubMed Web of Science ®Google Scholar
• Jin J. S., Hsieh D. S., Lin Y. F., et al. Increasing expression of extracellular matrix metalloprotease inducer in renal cell carcinoma. Tissue microarray analysis of immunostaining score with clinicopathological parameters. Int J Urol 2006; 13: 573–80
   PubMed Web of Science ®Google Scholar
• Leroy X., Zercmech F., Zini L., et al. MUC1 expression is correlated with nuclear grade and progression in TI renal cell carcinoma. Am J Clin Pathol 2002; 118: 47–51
   PubMed Web of Science ®Google Scholar
• Matusan K., Dordevic G., Stipic D., Mozetic V., Lucin K. Osteopontin expression correlates with prognostic variables and survival in clear cell renal cell carcinoma. J Surg Oncol 2006; 94: 325–31
   PubMed Web of Science ®Google Scholar
• Robson C. J., Churchill B. M., Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol 1969; 101: 297–301
   PubMed Web of Science ®Google Scholar
• Green F. L., Page D. L., Fleming I. D., et al. AJCC Cancer Staging Manual. 2002, 6th ed. Springer: New York
   Google Scholar
• Svatek R. S., Lotan Y., Hermann M., et al. The influence of clinical and pathological staging discrepancy on cancer specific survivals in patients treated for renal cell carcinoma. J Urol 2006; 176: 1321–5
   PubMed Web of Science ®Google Scholar
• Delahunt B., Eble J. N. Papillary adenoma of the kidney. An evolving concept. J Urol Pathol 1997; 7: 99–112
   Google Scholar
• Sobin L. H., Wittekind Ch. TNM Classification of Malignant Tumours. 1997, 5th ed. Wiley‐Liss: New York
   Google Scholar
• Gofrit O. N., Shapiro A., Pizov G., et al. Does stage T3a renal cell carcinoma embrace a homogenous group of patients?. J Urol 2007; 177: 2604–8
   Google Scholar
• Bonsib S. M. T2 clear cell renal cell carcinoma is a rare entity: a study of 120 clear cell renal cell carcinomas. J Urol 2005; 174: 1199–202
   PubMed Web of Science ®Google Scholar
• Thompson R. H., Leibovich B. C., Cheville J. C., et al. Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma?. J Urol 2005; 174: 1218–21
   PubMed Web of Science ®Google Scholar
• Bonsib S. M. Renal veins and venous extension in clear cell renal cell carcinoma. Mod Pathol 2007; 20: 44–53
   PubMed Web of Science ®Google Scholar
• Bonsib S. M. Renal lymphatics and lymphatic involvement in sinus vein invasive (pT3b) clear cell renal cell carcinoma. A study of 40 cases. Mod Pathol 2006; 19: 746–53
   PubMed Web of Science ®Google Scholar
• Leibovich B. C., Blute M. L., Cheville C. M., et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma. A stratification tool for prospective clinical trials. Cancer 2003; 97: 1663–71
   PubMed Web of Science ®Google Scholar
• Sorbollini M., Kattan M. W., Snyder M. E., et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 2005; 173: 48–51
   PubMed Web of Science ®Google Scholar
• Hupertan V., Roupret M., Poisson J. F., et al. Low predictive accuracy of the Kattan postoperative predictive nomogram for renal cell carcinoma recurrence in a population of French patients. Cancer 2006; 107: 2523–4
   PubMed Web of Science ®Google Scholar